SCHEMBL9105399

SCHEMBL9105399

CCC[C@@H](CN1CC(O)C1)N(C)C(=O)c1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 1/20 0.42
▸ UBE2M P61081 5/20 0.39
▸ DCUN1D1 Q96GG9 5/20 0.39
▸ TAS1R3 Q7RTX0 2/20 0.39
▸ TAS1R1 Q7RTX1 2/20 0.39
▸ TAS1R2 Q8TE23 2/20 0.39
▸ SLC6A9 P48067 2/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ GPBAR1 Q8TDU6 1/20 0.36
▸ OPRK1 P41145 2/20 0.35
▸ CCR5 P51681 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ DDR1 Q08345 1/20 0.34
▸ EPHX1 P07099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9105408 1.00 HDAC8 (0.42) HDAC8UBE2MDCUN1D1TAS1R3TAS1R1
SCHEMBL9105962 0.88 OPRK1 (0.37) TAS1R3TAS1R1TAS1R2OPRK1CCR5
SCHEMBL9104979 0.88 OPRK1 (0.37) TAS1R3TAS1R1TAS1R2OPRK1CCR5
SCHEMBL31478912 0.88 OPRK1 (0.37) TAS1R3TAS1R1TAS1R2OPRK1CCR5
SCHEMBL9102296 0.86 OPRK1 (0.36) OPRK1HRH3
SCHEMBL9102284 0.86 OPRK1 (0.36) OPRK1HRH3
SCHEMBL9100354 0.85 OPRK1 (0.43) UBE2MDCUN1D1TAS1R3TAS1R1TAS1R2
SCHEMBL31478849 0.85 OPRK1 (0.43) UBE2MDCUN1D1TAS1R3TAS1R1TAS1R2
SCHEMBL9100342 0.85 OPRK1 (0.43) UBE2MDCUN1D1TAS1R3TAS1R1TAS1R2
SCHEMBL9102141 0.85 CCR5 (0.43) CYP2D6OPRK1CCR5HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025082731-A1 INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA MOSANNA THERAPEUTICS AG (CH) 2025-04-24 — — WO disclosed
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2013-06-06 — — US disclosed
US-8361998-B2 Compounds and their use as IKACh blockers ASTRAZENECA AB 2013-01-29 — — US disclosed
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 HDAC8 1995/4885UBE2M 2018/4885DCUN1D1 2889/4885
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 HDAC8 1995/4885UBE2M 2018/4885DCUN1D1 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback